{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:35:30Z","timestamp":1783398930567,"version":"3.54.6"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Graves\u2019 ophthalmopathy (GO), also known as thyroid eye disease (TED), is the most common extrathyroidal manifestation of Graves\u2019 disease and a leading cause of visual morbidity. The disease primarily affects the orbital tissue and is characterized by inflammation, expansion of extraocular muscles, and remodeling of orbital fat, resulting in proptosis, diplopia, and even vision loss. Active GO poses significant therapeutic challenges and often requires prompt intervention to preserve visual function and improve quality of life. Over the past decade, considerable progress has been made in understanding the immunopathogenesis of GO, leading to the development of targeted pharmacological therapies that extend beyond traditional systemic corticosteroids. This review summarizes recent advances in the drug therapy of active GO, focusing on novel immunomodulators, biological agents such as monoclonal antibodies targeting CD20, IL-6 R, and insulin-like growth factor-1 receptor (IGF-1R), and evolving treatment strategies based on disease activity and severity. We also discuss current clinical practice guidelines, emerging therapeutic targets under investigation, and future perspectives in the individualized management of this vision-threatening autoimmune condition.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1647602","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T05:26:41Z","timestamp":1753421201000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Emerging therapeutic approaches in graves\u2019 ophthalmopathy: an update on pharmacological interventions"],"prefix":"10.3389","volume":"16","author":[{"given":"Lin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-01246-7","article-title":"Clinical features and clinical course of thyroid-associated ophthalmopathy: a case series of 3620 Chinese cases","volume":"35","author":"Du","year":"2021","journal-title":"Eye (Lond)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0189","article-title":"Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association","volume":"11","author":"Burch","year":"2022","journal-title":"Eur Thyroid J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13023-017-0625-1","article-title":"Graves\u2019 orbitopathy as a rare disease in Europe: a European Group on Graves\u2019 Orbitopathy (EUGOGO) position statement","volume":"12","author":"Perros","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-020-0184-y","article-title":"Graves\u2019 disease","volume":"6","author":"Davies","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2023-001443","article-title":"Increased choroidal stromal area in patients with active Graves\u2019 ophthalmopathy based on binarisation method of optical coherence tomographic images","volume":"9","author":"Zhou","year":"2024","journal-title":"BMJ Open Ophthalmol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2009.04322.x","article-title":"Prevention and treatment of systemic glucocorticoid side effects","volume":"49","author":"Moghadam-Kia","year":"2010","journal-title":"Int J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.12.007","article-title":"Rituximab treatment as second-line therapy in glucocorticoid nonresponsive graves\u2019 Orbitopathy: A nonrandomized, controlled, interventional study","volume":"31","author":"Manousou","year":"2025","journal-title":"Endocr Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: A randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.01.023","article-title":"Glycemic trends in patients with thyroid eye disease treated with teprotumumab in 3 clinical trials","volume":"131","author":"Smith","year":"2024","journal-title":"Ophthalmology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0311093","article-title":"Linsitinib inhibits IGF-1-induced cell proliferation and hyaluronic acid secretion by suppressing PI3K\/Akt and ERK pathway in orbital fibroblasts from patients with thyroid-associated ophthalmopathy","volume":"19","author":"Lee","year":"2024","journal-title":"PloS One"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqaf009","article-title":"Mechanisms in thyroid eye disease: the TSH receptor interacts directly with the IGF-1 receptor","volume":"166","author":"Latif","year":"2025","journal-title":"Endocrinology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1252727","article-title":"Potential involvement of the bone marrow in experimental Graves\u2019 disease and thyroid eye disease","volume":"14","author":"Gulbins","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01349","article-title":"Regulation of orbital fibrosis and adipogenesis by pathogenic th17 cells in graves orbitopathy","volume":"102","author":"Fang","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-023-00616-7","article-title":"Role and mechanism of CD90(+) fibroblasts in inflammatory diseases and Malignant tumors","volume":"29","author":"Zeng","year":"2023","journal-title":"Mol Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2025.167747","article-title":"Inflammatory and tolerogenic dendritic cells and T lymphocytes in Graves\u2019 thyroidal and orbital disease","volume":"1871","author":"Zeitrag","year":"2025","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cells13171493","article-title":"A review of pathophysiology and therapeutic strategies targeting TGF-beta in graves\u2019 Ophthalmopathy","volume":"13","author":"Chang","year":"2024","journal-title":"Cells"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105607","article-title":"TMEM2 inhibits the development of Graves\u2019 orbitopathy through the JAK-STAT signaling pathway","volume":"300","author":"Li","year":"2024","journal-title":"J Biol Chem"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1804","article-title":"Potential utility of rituximab for Graves\u2019 orbitopathy","volume":"98","author":"Salvi","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0269","article-title":"Efficacy profile and safety of very low-dose rituximab in patients with graves\u2019 Orbitopathy","volume":"31","author":"Vannucchi","year":"2021","journal-title":"Thyroid"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1079852","article-title":"Observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: One pilot study","volume":"13","author":"Wang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2024.109812","article-title":"GSDMD mediated pyroptosis induced inflammation of Graves\u2019 orbitopathy via the NF-kappaB\/AIM2\/Caspase-1 pathway","volume":"240","author":"Sha","year":"2024","journal-title":"Exp Eye Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.607144","article-title":"Role of proprotein convertase subtilisin\/kexin type 9 in the pathogenesis of graves\u2019 Orbitopathy in orbital fibroblasts","volume":"11","author":"Lee","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-024-01545-0","article-title":"Combined glucocorticoids and cyclophosphamide in the treatment of Graves\u2019 ophthalmopathy: a systematic review and meta-analysis","volume":"24","author":"Xiang","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2024-325180","article-title":"Effect of intravenous methylprednisolone on serum antibody levels in thyroid eye disease","volume":"109","author":"Lee","year":"2025","journal-title":"Br J Ophthalmol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1548953","article-title":"Negative association between serum calcium and glucocorticoid-induced hypertension in thyroid-associated ophthalmopathy patients treated with methylprednisolone","volume":"16","author":"Wang","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI63377","article-title":"Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism","volume":"122","author":"Brennan-Speranza","year":"2012","journal-title":"J Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-024-02967-9","article-title":"The changing landscape of thyroid eye disease: current clinical advances and future outlook","volume":"38","author":"Moledina","year":"2024","journal-title":"Eye (Lond)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/biom15030437","article-title":"Liver injury following intravenous methylprednisolone pulse therapy in multiple sclerosis: the experience from a single academic liver center","volume":"15","author":"Kounatidis","year":"2025","journal-title":"Biomolecules"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjopt.2017.09.003","article-title":"Review of the treatment of Graves\u2019 ophthalmopathy: The role of the new radiation techniques","volume":"32","author":"San Miguel","year":"2018","journal-title":"Saudi J Ophthalmol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13020061","article-title":"Orbital radiotherapy for graves\u2019 Ophthalmopathy: single institutional experience of efficacy and safety","volume":"13","author":"La Rocca","year":"2025","journal-title":"Diseases"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15071999","article-title":"Radiation-induced retinopathy and optic neuropathy after radiation therapy for brain, head, and neck tumors: A systematic review","volume":"15","author":"Kinaci-Tas","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4845894","article-title":"Corticosteroids for graves\u2019 Ophthalmopathy: systematic review and meta-analysis","volume":"2018","author":"Tu","year":"2018","journal-title":"BioMed Res Int"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1140196","article-title":"Therapeutic outcomes of mycophenolate mofetil and glucocorticoid in thyroid-associated ophthalmopathy patients","volume":"14","author":"Li","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-018-0315-9","article-title":"Interruption of autoimmunity for thyroid eye disease: B-cell and T-cell strategy","volume":"33","author":"Strianese","year":"2019","journal-title":"Eye (Lond)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.18.7.723","article-title":"The development of novel therapies for rheumatoid arthritis","volume":"18","author":"Quan","year":"2008","journal-title":"Expert Opin Ther Pat"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2018.1453078","article-title":"Low-dose rituximab for active moderate to severe graves\u2019 Orbitopathy resistant to conventional treatment","volume":"27","author":"Du Pasquier-Fediaevsky","year":"2019","journal-title":"Ocul Immunol Inflammation"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-020-04651-6","article-title":"Efficacy of rituximab in patients with Graves\u2019 orbitopathy: a retrospective multicenter nationwide study","volume":"258","author":"Deltour","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1808688","article-title":"Tocilizumab versus rituximab in patients with moderate to severe steroid-resistant graves\u2019 Orbitopathy","volume":"30","author":"Bennedjai","year":"2022","journal-title":"Ocul Immunol Inflammation"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2025.01.012","article-title":"Efficacy and safety of teprotumumab in thyroid eye disease: A systematic review and meta-analysis","author":"Huang","year":"2025","journal-title":"Endocr Pract"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae417","article-title":"Postmarketing safety concerns of teprotumumab: A real-world pharmacovigilance assessment","volume":"110","author":"Huang","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1186105","article-title":"Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves\u2019 orbitopathy: an observational study","volume":"14","author":"Boutzios","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252111628","article-title":"A comprehensive review of thyroid eye disease pathogenesis: from immune dysregulations to novel diagnostic and therapeutic approaches","volume":"25","author":"Kulbay","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002573","article-title":"Efficiency and safety of tocilizumab for the treatment of thyroid eye disease: A systematic review","volume":"40","author":"Duarte","year":"2024","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1160936","article-title":"Efficacy and Safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves\u2019ophthalmopathy: a systematic review and meta-analysis","volume":"14","author":"Hu","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex221","article-title":"Toxic drug-induced liver failure during therapy of rheumatoid arthritis with tocilizumab subcutaneously: a case report","volume":"56","author":"Anger","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.5603\/ep.98913","article-title":"The position of monoclonal antibodies and small molecules in the treatment of thyroid orbitopathy","volume":"75","author":"Nowak","year":"2024","journal-title":"Endokrynol Pol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2009.02093.x","article-title":"Graves\u2019 ophthalmopathy and gene polymorphisms in interleukin-1alpha, interleukin-1beta, interleukin-1 receptor and interleukin-1 receptor antagonist","volume":"37","author":"Khalilzadeh","year":"2009","journal-title":"Clin\u00a0Exp Ophthalmol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy","volume":"90","author":"Kahaly","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00238-2","article-title":"Statins for Graves\u2019 orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial","volume":"9","author":"Lanzolla","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.04.024","article-title":"Teprotumumab: interpreting the clinical trials in the context of thyroid eye disease pathogenesis and current therapies","volume":"128","author":"Winn","year":"2021","journal-title":"Ophthalmology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2025.101464","article-title":"A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients","volume":"55","author":"Hiromatsu","year":"2025","journal-title":"Lancet Reg Health West Pac"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12999","article-title":"Influence of 4-week or 12-week glucocorticoid treatment on metabolic changes in patients with active moderate-to-severe thyroid-associated ophthalmopathy","volume":"14","author":"Chen","year":"2021","journal-title":"Clin Transl Sci"},{"key":"B62","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s13318-024-00927-y","article-title":"Evaluation of the clinical outcomes of cyclosporine short infusion versus continuous infusion postallogenic stem cell transplantation","volume":"50","author":"El-Awady","year":"2025","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjo.2015.03.004","article-title":"Immunosuppressive therapy for eye diseases: Effectiveness, safety, side effects and their prevention","volume":"5","author":"Hornbeak","year":"2015","journal-title":"Taiwan J Ophthalmol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1647602\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T05:26:41Z","timestamp":1753421201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1647602\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2025.1647602"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1647602","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"article-number":"1647602"}}